Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
First published online on April 10, 2008
Chest, doi:10.1378/chest.07-2751
doi:10.1378/chest.07-2751
(Chest. 2008; 134:346-350)
© 2008 American College of Chest Physicians
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
chest.07-2751v1
134/2/346    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Sierra-Johnson, J.
Right arrow Articles by Johnson, B. D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sierra-Johnson, J.
Right arrow Articles by Johnson, B. D.

Leptin, a Novel Predictor of Lung Function in Heart Failure*

Justo Sierra-Johnson, MD, MS; Abel Romero-Corral, MD, MS; Virend K. Somers, MD, PhD, FCCP; Lyle J. Olson, MD and Bruce D. Johnson, PhD

* From the Division of Cardiovascular Diseases, Department of Internal Medicine (Drs. Romero-Corral, Somers, Olson, and Johnson), and the Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic and Foundation, Rochester MN; and the Atherosclerosis Research Unit, Department of Medicine (Dr. Sierra-Johnson), Karolinska Institutet, Stockholm, Sweden.

Correspondence to: Bruce D. Johnson, PhD, 200 First St SW, Gonda 5-368, Rochester MN 55905, e-mail: johnson.bruce{at}mayo.edu

Abstract

Background: Leptin is a protein hormone produced by adipose tissue. Leptin has proinflammatory properties and is usually elevated in patients with chronic heart failure. We assessed if serum leptin relates to the loss in lung function in noncachectic patients with chronic heart failure.

Materials and methods: One hundred thirty-five consecutively eligible non-Hispanic white subjects (age, 24 to 79 years; 85 men and 50 women) with a diagnosis of stable systolic heart failure were recruited prospectively, along with 106 matched control subjects. FVC, FEV1, and single-breath diffusing capacity of the lung for carbon monoxide (DLCO) were measured by spirometry. Plasma leptin was measured by radioimmunoassay. Multiple linear regression was applied.

Results: The relationships of FEV1, FVC, and DLCO with leptin differed significantly between heart failure and control subjects after controlling for age, sex, percentage of body fat, and ejection fraction. In heart failure, leptin was as an independent predictor of FVC values (additional R2 = 0.05, p < 0.0001), FEV1 values (additional R2 = 0.05, p < 0.0001), and DLCO values (additional R2 = 0.14, p < 0.0001). In a final multiple regression model predicting lung function in heart failure, the independent effect of leptin was significant after further adjustments.

Conclusions: The predictive information provided by leptin is additive to that provided by measures of body fat in heart failure patients, especially for DLCO. Leptin may play a role in the impairment of lung function in subjects with heart failure.

Key Words: body fat • heart failure • leptin • lung






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American College of Chest Physicians.